• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
CYP 8.57% 19.0¢

CYNATA THERAPEUTICS LIMITED

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
CYP
Going forward...
34 35 36
18:59 2.1K 666K
18:59 Last post  gavint66 Comments Created with Sketch.  2.1K  Views Created with Sketch.  666K 
CYP 24/03/24 58 9.3K
24/03/24 Last post  JB1975 Comments Created with Sketch.  58  Views Created with Sketch.  9.3K 
CYP 22/03/24 8 1.3K
TRENDING NEWS

Diversification and low trading fees: Is this the ‘secret sauce’ to saving your investment portfolio?

NEWS
28 Mar 2024
22/03/24 Last post  OceanView Comments Created with Sketch.  8  Views Created with Sketch.  1.3K 
CYP
The Phase I/IIb Nereid Study Is Now Registered
22/03/24 19 2.8K
22/03/24 Last post  truss20 Comments Created with Sketch.  19  Views Created with Sketch.  2.8K 
CYP
News: CYP Cynata Therapeutics Gets EU Regulatory & Ethics Approval For Phase 2 Trial In Graft...
20/03/24 1 283
20/03/24 Last post  Pledge Comments Created with Sketch.  1  Views Created with Sketch.  283 
CYP
Stem Cell News
7 8 9
20/03/24 511 115K
20/03/24 Last post  bedger Comments Created with Sketch.  511  Views Created with Sketch.  115K 
CYP 18/03/24 0 307
18/03/24 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  307 
CYP
CYP chart
31 32 33
08/03/24 1.9K 576K
08/03/24 Last post  nippy Comments Created with Sketch.  1.9K  Views Created with Sketch.  576K 

See All Discussions arrow Created with Sketch.

Timeline

EU Approval for Phase 2 CYP-001 Trial in GvHD
20 Mar 08:55
 
Cynata Presenting at Advanced Therapies Congress
18 Mar 08:52
 
First Patient Treated in Phase 2 GvHD Trial
05 Mar 08:54
 
Cynata Appoints New Chief Business Officer
29 Feb 09:19
 
Encouraging Initial Data from CYP-006TK DFU Trial
26 Feb 09:01
 
Appendix 4D & Half-Year Financial Statements
23 Feb 15:22
 
View More arrow Created with Sketch.
(20min delay)
Last
19.0¢
Change
0.015(8.57%)
Mkt cap ! $34.13M
Open High Low Value Volume
18.5¢ 19.0¢ 18.5¢ $7.936K 41.94K

Buyers (Bids)

No. Vol. Price($)
1 37413 18.0¢
 

Sellers (Offers)

Price($) Vol. No.
19.0¢ 7290 1
View Market Depth
Last trade - 16.10pm 28/03/2024 (20 minute delay) ?
Last
19.5¢
  Change
0.015 ( 11.4 %)
Open High Low Volume
18.5¢ 19.5¢ 18.5¢ 5805
Last updated 15.29pm 28/03/2024 ?
CYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.